# PeptideScanner evidence objects: Eloralintide

Every published version of the records placed with Eloralintide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/eloralintide.json. Selected public evidence only; not medical advice.

- Objects: 20
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct06230523-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT06230523

> PeptideScanner retained ClinicalTrials.gov record NCT06230523 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct06230523-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06230523-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct06230523-eloralintide-v1
- Content SHA-256: `fa84d5661a90a4b2990f31cb7a4ad6787afe3789958266488d7085a62656d103`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06230523 ([`ctg-observation-nct06230523-2026-06-24-750931bc2316`](#source-ctg-observation-nct06230523-2026-06-24-750931bc2316))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06230523 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct06230523-2026-06-24-750931bc2316`](#source-ctg-observation-nct06230523-2026-06-24-750931bc2316))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06230523 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct06230523-2026-06-24-750931bc2316`](#source-ctg-observation-nct06230523-2026-06-24-750931bc2316))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06230523-2026-06-24-750931bc2316`](#source-ctg-observation-nct06230523-2026-06-24-750931bc2316))

### Sources

<a id="source-ctg-observation-nct06230523-2026-06-24-750931bc2316"></a>
- **ClinicalTrials.gov record NCT06230523 · retained source version 2026-06-24:750931bc2316cf26cdcc994abc57cfb44542bdea9592c1e7618572bb2dc2c40a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06230523) (`ctg-observation-nct06230523-2026-06-24-750931bc2316`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06230523." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct06230523-eloralintide-v1 SHA-256: fa84d5661a90a4b2990f31cb7a4ad6787afe3789958266488d7085a62656d103.

---

<a id="clinicaltrials-gov-nct06916065-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT06916065

> PeptideScanner retained ClinicalTrials.gov record NCT06916065 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct06916065-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06916065-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct06916065-eloralintide-v1
- Content SHA-256: `e41cf99cbcded274d51af33e67ba8b00901caf7e31cd8eff5bc5f273b8e6c228`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06916065 ([`ctg-observation-nct06916065-2026-01-30-cab98e30833f`](#source-ctg-observation-nct06916065-2026-01-30-cab98e30833f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06916065 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct06916065-2026-01-30-cab98e30833f`](#source-ctg-observation-nct06916065-2026-01-30-cab98e30833f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06916065 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct06916065-2026-01-30-cab98e30833f`](#source-ctg-observation-nct06916065-2026-01-30-cab98e30833f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06916065-2026-01-30-cab98e30833f`](#source-ctg-observation-nct06916065-2026-01-30-cab98e30833f))

### Sources

<a id="source-ctg-observation-nct06916065-2026-01-30-cab98e30833f"></a>
- **ClinicalTrials.gov record NCT06916065 · retained source version 2026-01-30:cab98e30833f88708fad965e3e69492a714d9e8e7bc9b6226aa7e3aab358643d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06916065) (`ctg-observation-nct06916065-2026-01-30-cab98e30833f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06916065." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct06916065-eloralintide-v1 SHA-256: e41cf99cbcded274d51af33e67ba8b00901caf7e31cd8eff5bc5f273b8e6c228.

---

<a id="clinicaltrials-gov-nct06916091-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT06916091

> PeptideScanner retained ClinicalTrials.gov record NCT06916091 at 2026-11-16T01:48:01.052Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct06916091-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06916091-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct06916091-eloralintide-v1
- Content SHA-256: `dc903f25d15e3e18cf736a1d511da2e40326c664e91b52b163a0b17a6e186d75`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06916091 ([`ctg-observation-nct06916091-2025-11-19-f7e61f89d038`](#source-ctg-observation-nct06916091-2025-11-19-f7e61f89d038))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06916091 at 2026-11-16T01:48:01.052Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct06916091-2025-11-19-f7e61f89d038`](#source-ctg-observation-nct06916091-2025-11-19-f7e61f89d038))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06916091 at 2026-11-16T01:48:01.052Z. Its registry update date was 2025-11-19, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct06916091-2025-11-19-f7e61f89d038`](#source-ctg-observation-nct06916091-2025-11-19-f7e61f89d038))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06916091-2025-11-19-f7e61f89d038`](#source-ctg-observation-nct06916091-2025-11-19-f7e61f89d038))

### Sources

<a id="source-ctg-observation-nct06916091-2025-11-19-f7e61f89d038"></a>
- **ClinicalTrials.gov record NCT06916091 · retained source version 2025-11-19:f7e61f89d038d38393f6d07de9ff887f7c0fc0d0f397f29fb0ea002a57765df2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06916091) (`ctg-observation-nct06916091-2025-11-19-f7e61f89d038`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06916091." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct06916091-eloralintide-v1 SHA-256: dc903f25d15e3e18cf736a1d511da2e40326c664e91b52b163a0b17a6e186d75.

---

<a id="clinicaltrials-gov-nct07215559-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07215559

> PeptideScanner retained ClinicalTrials.gov record NCT07215559 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-09, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07215559-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07215559-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07215559-eloralintide-v1
- Content SHA-256: `51ea26403346c5ecf7fc7bd86f4deee3d285d8782b854988422d7b4a3507451b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07215559 ([`ctg-observation-nct07215559-2026-10-09-0f1814220c18`](#source-ctg-observation-nct07215559-2026-10-09-0f1814220c18))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07215559 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-09, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07215559-2026-10-09-0f1814220c18`](#source-ctg-observation-nct07215559-2026-10-09-0f1814220c18))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07215559 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-09, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07215559-2026-10-09-0f1814220c18`](#source-ctg-observation-nct07215559-2026-10-09-0f1814220c18))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07215559-2026-10-09-0f1814220c18`](#source-ctg-observation-nct07215559-2026-10-09-0f1814220c18))

### Sources

<a id="source-ctg-observation-nct07215559-2026-10-09-0f1814220c18"></a>
- **ClinicalTrials.gov record NCT07215559 · retained source version 2026-10-09:0f1814220c18da2de386f1484ec5630d92d7e599e486f208bb045a999f338472** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07215559) (`ctg-observation-nct07215559-2026-10-09-0f1814220c18`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07215559." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07215559-eloralintide-v1 SHA-256: 51ea26403346c5ecf7fc7bd86f4deee3d285d8782b854988422d7b4a3507451b.

---

<a id="clinicaltrials-gov-nct07282600-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07282600

> PeptideScanner retained ClinicalTrials.gov record NCT07282600 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07282600-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07282600-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07282600-eloralintide-v1
- Content SHA-256: `2948790c5cf56d73600d82242a85106ca80b69a9bbefb4da6d3d951637a3343f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07282600 ([`ctg-observation-nct07282600-2026-11-04-911b1960e314`](#source-ctg-observation-nct07282600-2026-11-04-911b1960e314))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07282600 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07282600-2026-11-04-911b1960e314`](#source-ctg-observation-nct07282600-2026-11-04-911b1960e314))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07282600 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07282600-2026-11-04-911b1960e314`](#source-ctg-observation-nct07282600-2026-11-04-911b1960e314))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07282600-2026-11-04-911b1960e314`](#source-ctg-observation-nct07282600-2026-11-04-911b1960e314))

### Sources

<a id="source-ctg-observation-nct07282600-2026-11-04-911b1960e314"></a>
- **ClinicalTrials.gov record NCT07282600 · retained source version 2026-11-04:911b1960e3148af61c900186c05d80428623659df3872bfdb9ba3e0b58d2ce68** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07282600) (`ctg-observation-nct07282600-2026-11-04-911b1960e314`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07282600." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07282600-eloralintide-v1 SHA-256: 2948790c5cf56d73600d82242a85106ca80b69a9bbefb4da6d3d951637a3343f.

---

<a id="clinicaltrials-gov-nct07321886-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07321886

> PeptideScanner retained ClinicalTrials.gov record NCT07321886 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07321886-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07321886-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07321886-eloralintide-v1
- Content SHA-256: `358b48efb21bdf4826c706c5ffa7785d691b45a2220ab1736341b5409bb346ea`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07321886 ([`ctg-observation-nct07321886-2026-09-22-853c308f9115`](#source-ctg-observation-nct07321886-2026-09-22-853c308f9115))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07321886 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07321886-2026-09-22-853c308f9115`](#source-ctg-observation-nct07321886-2026-09-22-853c308f9115))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07321886 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-22, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07321886-2026-09-22-853c308f9115`](#source-ctg-observation-nct07321886-2026-09-22-853c308f9115))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07321886-2026-09-22-853c308f9115`](#source-ctg-observation-nct07321886-2026-09-22-853c308f9115))

### Sources

<a id="source-ctg-observation-nct07321886-2026-09-22-853c308f9115"></a>
- **ClinicalTrials.gov record NCT07321886 · retained source version 2026-09-22:853c308f9115135e14872b98fe113b21ed3bfd2bf85ee60f72affd9103c5f058** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07321886) (`ctg-observation-nct07321886-2026-09-22-853c308f9115`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07321886." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07321886-eloralintide-v1 SHA-256: 358b48efb21bdf4826c706c5ffa7785d691b45a2220ab1736341b5409bb346ea.

---

<a id="clinicaltrials-gov-nct07353931-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07353931

> PeptideScanner retained ClinicalTrials.gov record NCT07353931 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07353931-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07353931-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07353931-eloralintide-v1
- Content SHA-256: `af2342ce7529c3d59436719bf2a1ecb1679e81d544b2fac5f8aa198014835481`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07353931 ([`ctg-observation-nct07353931-2026-11-04-be753ffcfe70`](#source-ctg-observation-nct07353931-2026-11-04-be753ffcfe70))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07353931 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07353931-2026-11-04-be753ffcfe70`](#source-ctg-observation-nct07353931-2026-11-04-be753ffcfe70))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07353931 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07353931-2026-11-04-be753ffcfe70`](#source-ctg-observation-nct07353931-2026-11-04-be753ffcfe70))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07353931-2026-11-04-be753ffcfe70`](#source-ctg-observation-nct07353931-2026-11-04-be753ffcfe70))

### Sources

<a id="source-ctg-observation-nct07353931-2026-11-04-be753ffcfe70"></a>
- **ClinicalTrials.gov record NCT07353931 · retained source version 2026-11-04:be753ffcfe702bced4354977a9b85db8f84552fe7410c39e988f4f276610507c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07353931) (`ctg-observation-nct07353931-2026-11-04-be753ffcfe70`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07353931." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07353931-eloralintide-v1 SHA-256: af2342ce7529c3d59436719bf2a1ecb1679e81d544b2fac5f8aa198014835481.

---

<a id="clinicaltrials-gov-nct07369011-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07369011

> PeptideScanner retained ClinicalTrials.gov record NCT07369011 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07369011-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07369011-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07369011-eloralintide-v1
- Content SHA-256: `04a560653634b780c2bc550b31444b0cdbba52f346f6b39bbdb28e2b3d02388a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07369011 ([`ctg-observation-nct07369011-2026-11-04-968753a1a8c3`](#source-ctg-observation-nct07369011-2026-11-04-968753a1a8c3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07369011 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07369011-2026-11-04-968753a1a8c3`](#source-ctg-observation-nct07369011-2026-11-04-968753a1a8c3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07369011 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07369011-2026-11-04-968753a1a8c3`](#source-ctg-observation-nct07369011-2026-11-04-968753a1a8c3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07369011-2026-11-04-968753a1a8c3`](#source-ctg-observation-nct07369011-2026-11-04-968753a1a8c3))

### Sources

<a id="source-ctg-observation-nct07369011-2026-11-04-968753a1a8c3"></a>
- **ClinicalTrials.gov record NCT07369011 · retained source version 2026-11-04:968753a1a8c36a1c4cf24c5469b814552e751bf040a09ba642cb216c9db2ac1b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07369011) (`ctg-observation-nct07369011-2026-11-04-968753a1a8c3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07369011." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07369011-eloralintide-v1 SHA-256: 04a560653634b780c2bc550b31444b0cdbba52f346f6b39bbdb28e2b3d02388a.

---

<a id="clinicaltrials-gov-nct07392190-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07392190

> PeptideScanner retained ClinicalTrials.gov record NCT07392190 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07392190-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07392190-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07392190-eloralintide-v1
- Content SHA-256: `3425d8dc7651412b7fcedb1de1be7ef3a3ff6f7c346b89773242caabdea48089`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07392190 ([`ctg-observation-nct07392190-2026-11-04-0af413acc457`](#source-ctg-observation-nct07392190-2026-11-04-0af413acc457))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07392190 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07392190-2026-11-04-0af413acc457`](#source-ctg-observation-nct07392190-2026-11-04-0af413acc457))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07392190 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07392190-2026-11-04-0af413acc457`](#source-ctg-observation-nct07392190-2026-11-04-0af413acc457))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07392190-2026-11-04-0af413acc457`](#source-ctg-observation-nct07392190-2026-11-04-0af413acc457))

### Sources

<a id="source-ctg-observation-nct07392190-2026-11-04-0af413acc457"></a>
- **ClinicalTrials.gov record NCT07392190 · retained source version 2026-11-04:0af413acc457030df4c2a50014ebc6f3398dd4d5a38d03480f1cc1d57657339c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07392190) (`ctg-observation-nct07392190-2026-11-04-0af413acc457`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07392190." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07392190-eloralintide-v1 SHA-256: 3425d8dc7651412b7fcedb1de1be7ef3a3ff6f7c346b89773242caabdea48089.

---

<a id="clinicaltrials-gov-nct07401862-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07401862

> PeptideScanner retained ClinicalTrials.gov record NCT07401862 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07401862-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07401862-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07401862-eloralintide-v1
- Content SHA-256: `7479a25c76a8ae80425f92f60eac4b590fe57120ed1fde51a796de0ac9928fa8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07401862 ([`ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf`](#source-ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07401862 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf`](#source-ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07401862 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf`](#source-ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf`](#source-ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf))

### Sources

<a id="source-ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf"></a>
- **ClinicalTrials.gov record NCT07401862 · retained source version 2026-06-04:f8c8e9a7bbbfe3822d9d9bba1a58bcb0752d46748329bff7be7155c261e6291a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07401862) (`ctg-observation-nct07401862-2026-06-04-f8c8e9a7bbbf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07401862." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07401862-eloralintide-v1 SHA-256: 7479a25c76a8ae80425f92f60eac4b590fe57120ed1fde51a796de0ac9928fa8.

---

<a id="clinicaltrials-gov-nct07426380-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07426380

> PeptideScanner retained ClinicalTrials.gov record NCT07426380 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07426380-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07426380-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07426380-eloralintide-v1
- Content SHA-256: `7d76d190de14a6a2b2e07ed4b5b08d1a621ab0ed3b1d8293201a37b5ecaa440c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07426380 ([`ctg-observation-nct07426380-2026-08-19-09bb82851d1f`](#source-ctg-observation-nct07426380-2026-08-19-09bb82851d1f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07426380 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07426380-2026-08-19-09bb82851d1f`](#source-ctg-observation-nct07426380-2026-08-19-09bb82851d1f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07426380 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07426380-2026-08-19-09bb82851d1f`](#source-ctg-observation-nct07426380-2026-08-19-09bb82851d1f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07426380-2026-08-19-09bb82851d1f`](#source-ctg-observation-nct07426380-2026-08-19-09bb82851d1f))

### Sources

<a id="source-ctg-observation-nct07426380-2026-08-19-09bb82851d1f"></a>
- **ClinicalTrials.gov record NCT07426380 · retained source version 2026-08-19:09bb82851d1f73451c3820cdb1f467a50aa44306eed126295afe581d06d2608a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07426380) (`ctg-observation-nct07426380-2026-08-19-09bb82851d1f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07426380." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07426380-eloralintide-v1 SHA-256: 7d76d190de14a6a2b2e07ed4b5b08d1a621ab0ed3b1d8293201a37b5ecaa440c.

---

<a id="clinicaltrials-gov-nct07589608-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07589608

> PeptideScanner retained ClinicalTrials.gov record NCT07589608 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07589608-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07589608-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07589608-eloralintide-v1
- Content SHA-256: `386de6e297a7648ac7e16ba0fd0798949dac3cefc18b51079ffef0a9d8646cf4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07589608 ([`ctg-observation-nct07589608-2026-10-08-cb78699033f7`](#source-ctg-observation-nct07589608-2026-10-08-cb78699033f7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07589608 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07589608-2026-10-08-cb78699033f7`](#source-ctg-observation-nct07589608-2026-10-08-cb78699033f7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07589608 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07589608-2026-10-08-cb78699033f7`](#source-ctg-observation-nct07589608-2026-10-08-cb78699033f7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07589608-2026-10-08-cb78699033f7`](#source-ctg-observation-nct07589608-2026-10-08-cb78699033f7))

### Sources

<a id="source-ctg-observation-nct07589608-2026-10-08-cb78699033f7"></a>
- **ClinicalTrials.gov record NCT07589608 · retained source version 2026-10-08:cb78699033f7e7615a25557a3d566a76402246ae634a20fcf2c496b805f1f745** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07589608) (`ctg-observation-nct07589608-2026-10-08-cb78699033f7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07589608." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07589608-eloralintide-v1 SHA-256: 386de6e297a7648ac7e16ba0fd0798949dac3cefc18b51079ffef0a9d8646cf4.

---

<a id="clinicaltrials-gov-nct07665879-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07665879

> PeptideScanner retained ClinicalTrials.gov record NCT07665879 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07665879-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07665879-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07665879-eloralintide-v1
- Content SHA-256: `0c8ed7f9aa9fbc1acf8ae3830954a9eeb22b593bd78a9bc5f0ef4756506c3cab`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07665879 ([`ctg-observation-nct07665879-2026-07-16-021b9f609d08`](#source-ctg-observation-nct07665879-2026-07-16-021b9f609d08))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07665879 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07665879-2026-07-16-021b9f609d08`](#source-ctg-observation-nct07665879-2026-07-16-021b9f609d08))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07665879 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07665879-2026-07-16-021b9f609d08`](#source-ctg-observation-nct07665879-2026-07-16-021b9f609d08))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07665879-2026-07-16-021b9f609d08`](#source-ctg-observation-nct07665879-2026-07-16-021b9f609d08))

### Sources

<a id="source-ctg-observation-nct07665879-2026-07-16-021b9f609d08"></a>
- **ClinicalTrials.gov record NCT07665879 · retained source version 2026-07-16:021b9f609d0879d1426252c5fa2977759253d3b43910b0fbd3e53d011fb81b1f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07665879) (`ctg-observation-nct07665879-2026-07-16-021b9f609d08`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07665879." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07665879-eloralintide-v1 SHA-256: 0c8ed7f9aa9fbc1acf8ae3830954a9eeb22b593bd78a9bc5f0ef4756506c3cab.

---

<a id="clinicaltrials-gov-nct07701083-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07701083

> PeptideScanner retained ClinicalTrials.gov record NCT07701083 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07701083-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07701083-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07701083-eloralintide-v1
- Content SHA-256: `79a8dc022d73f0c2c52e2efd8ed8ce8e6164d4d736b99f44c60503c4f79502bc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07701083 ([`ctg-observation-nct07701083-2026-09-29-75350fc91e30`](#source-ctg-observation-nct07701083-2026-09-29-75350fc91e30))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07701083 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07701083-2026-09-29-75350fc91e30`](#source-ctg-observation-nct07701083-2026-09-29-75350fc91e30))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07701083 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07701083-2026-09-29-75350fc91e30`](#source-ctg-observation-nct07701083-2026-09-29-75350fc91e30))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07701083-2026-09-29-75350fc91e30`](#source-ctg-observation-nct07701083-2026-09-29-75350fc91e30))

### Sources

<a id="source-ctg-observation-nct07701083-2026-09-29-75350fc91e30"></a>
- **ClinicalTrials.gov record NCT07701083 · retained source version 2026-09-29:75350fc91e301cc41000779bf683606efa84c8ec8889078b03577bcc4465bd06** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07701083) (`ctg-observation-nct07701083-2026-09-29-75350fc91e30`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07701083." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07701083-eloralintide-v1 SHA-256: 79a8dc022d73f0c2c52e2efd8ed8ce8e6164d4d736b99f44c60503c4f79502bc.

---

<a id="clinicaltrials-gov-nct07738614-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07738614

> PeptideScanner retained ClinicalTrials.gov record NCT07738614 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-20, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07738614-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07738614-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07738614-eloralintide-v1
- Content SHA-256: `ad4a144cb6b3d749858953fb0f72a03a8785d9de7ba38f935fa6b44c26acdf83`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07738614 ([`ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e`](#source-ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07738614 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-20, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e`](#source-ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07738614 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-20, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e`](#source-ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e`](#source-ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e))

### Sources

<a id="source-ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e"></a>
- **ClinicalTrials.gov record NCT07738614 · retained source version 2026-08-20:c1cdd4779a0efca83818c90a18b41f63505b5e99a6082e6fe0d631ba5a458035** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07738614) (`ctg-observation-nct07738614-2026-08-20-c1cdd4779a0e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07738614." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07738614-eloralintide-v1 SHA-256: ad4a144cb6b3d749858953fb0f72a03a8785d9de7ba38f935fa6b44c26acdf83.

---

<a id="clinicaltrials-gov-nct07765511-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07765511

> PeptideScanner retained ClinicalTrials.gov record NCT07765511 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07765511-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07765511-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07765511-eloralintide-v1
- Content SHA-256: `5741c2c08942b36403219eabf758fa6477a032ffeac8c31f35c0cf1c9422ff4d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07765511 ([`ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3`](#source-ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07765511 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3`](#source-ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07765511 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-08-14, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3`](#source-ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3`](#source-ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3))

### Sources

<a id="source-ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3"></a>
- **ClinicalTrials.gov record NCT07765511 · retained source version 2026-08-14:8f51d54d0dc33406b1b0b4f01eed8a82b54b7f51bc1ece270cceb2a38bc31ffc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07765511) (`ctg-observation-nct07765511-2026-08-14-8f51d54d0dc3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07765511." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07765511-eloralintide-v1 SHA-256: 5741c2c08942b36403219eabf758fa6477a032ffeac8c31f35c0cf1c9422ff4d.

---

<a id="clinicaltrials-gov-nct07808060-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07808060

> PeptideScanner retained ClinicalTrials.gov record NCT07808060 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07808060-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07808060-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07808060-eloralintide-v1
- Content SHA-256: `ecfbd03c574b45f347065e260a5935534610834775208c503dee460ee9997cc4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07808060 ([`ctg-observation-nct07808060-2026-10-08-a1763c2e9f90`](#source-ctg-observation-nct07808060-2026-10-08-a1763c2e9f90))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07808060 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07808060-2026-10-08-a1763c2e9f90`](#source-ctg-observation-nct07808060-2026-10-08-a1763c2e9f90))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07808060 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07808060-2026-10-08-a1763c2e9f90`](#source-ctg-observation-nct07808060-2026-10-08-a1763c2e9f90))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07808060-2026-10-08-a1763c2e9f90`](#source-ctg-observation-nct07808060-2026-10-08-a1763c2e9f90))

### Sources

<a id="source-ctg-observation-nct07808060-2026-10-08-a1763c2e9f90"></a>
- **ClinicalTrials.gov record NCT07808060 · retained source version 2026-10-08:a1763c2e9f9027efbeb900d339d89dc2cdfe849a9a4d9c4fc1eecb440b4577da** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07808060) (`ctg-observation-nct07808060-2026-10-08-a1763c2e9f90`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07808060." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07808060-eloralintide-v1 SHA-256: ecfbd03c574b45f347065e260a5935534610834775208c503dee460ee9997cc4.

---

<a id="clinicaltrials-gov-nct07900633-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07900633

> PeptideScanner retained ClinicalTrials.gov record NCT07900633 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07900633-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07900633-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07900633-eloralintide-v1
- Content SHA-256: `bd4e8190b3367f4eb5b8da2b54188fd35bdabbd788e95cac8240ba5e6e3987ce`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07900633 ([`ctg-observation-nct07900633-2026-11-03-ed11d3680fa9`](#source-ctg-observation-nct07900633-2026-11-03-ed11d3680fa9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07900633 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07900633-2026-11-03-ed11d3680fa9`](#source-ctg-observation-nct07900633-2026-11-03-ed11d3680fa9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07900633 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07900633-2026-11-03-ed11d3680fa9`](#source-ctg-observation-nct07900633-2026-11-03-ed11d3680fa9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07900633-2026-11-03-ed11d3680fa9`](#source-ctg-observation-nct07900633-2026-11-03-ed11d3680fa9))

### Sources

<a id="source-ctg-observation-nct07900633-2026-11-03-ed11d3680fa9"></a>
- **ClinicalTrials.gov record NCT07900633 · retained source version 2026-11-03:ed11d3680fa9c954e00494097323f9e28cf97f4620226174b181d19cbd9d4695** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07900633) (`ctg-observation-nct07900633-2026-11-03-ed11d3680fa9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07900633." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07900633-eloralintide-v1 SHA-256: bd4e8190b3367f4eb5b8da2b54188fd35bdabbd788e95cac8240ba5e6e3987ce.

---

<a id="clinicaltrials-gov-nct07935304-eloralintide-v1"></a>

## ClinicalTrials.gov record NCT07935304

> PeptideScanner retained ClinicalTrials.gov record NCT07935304 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was eloralintide.

- Evidence object: `story:clinicaltrials-gov-nct07935304-eloralintide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07935304-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07935304-eloralintide-v1
- Content SHA-256: `4a71c09a2df43e3b2490afbb64a22b17e6ee5bfb70eb04c22ed22495942ac306`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07935304 ([`ctg-observation-nct07935304-2026-11-13-ef911b4c07cc`](#source-ctg-observation-nct07935304-2026-11-13-ef911b4c07cc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07935304 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07935304-2026-11-13-ef911b4c07cc`](#source-ctg-observation-nct07935304-2026-11-13-ef911b4c07cc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07935304 at 2026-11-16T01:48:01.052Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was eloralintide. ([`ctg-observation-nct07935304-2026-11-13-ef911b4c07cc`](#source-ctg-observation-nct07935304-2026-11-13-ef911b4c07cc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07935304-2026-11-13-ef911b4c07cc`](#source-ctg-observation-nct07935304-2026-11-13-ef911b4c07cc))

### Sources

<a id="source-ctg-observation-nct07935304-2026-11-13-ef911b4c07cc"></a>
- **ClinicalTrials.gov record NCT07935304 · retained source version 2026-11-13:ef911b4c07cc6ce32e8d99c4582274fe80dcc4b82891b7246379d208a5ef70f3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07935304) (`ctg-observation-nct07935304-2026-11-13-ef911b4c07cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07935304." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#clinicaltrials-gov-nct07935304-eloralintide-v1 SHA-256: 4a71c09a2df43e3b2490afbb64a22b17e6ee5bfb70eb04c22ed22495942ac306.

---

<a id="pubmed-pmid-41559929-eloralintide-v1"></a>

## Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

> PubMed lists PMID 41559929 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Multicenter Study, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug eloralintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41559929-eloralintide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41559929-eloralintide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#pubmed-pmid-41559929-eloralintide-v1
- Content SHA-256: `c962511e5cc60853f11258ae95d6d46942e08dbab9a3cea8e07aa87cf3f97694`

### Claims and source pins

#### Headline

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. ([`pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2`](#source-pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2))

#### Summary

PubMed lists PMID 41559929 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Multicenter Study, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug eloralintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2`](#source-pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2))

#### Paragraph 1

PubMed lists PMID 41559929 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Multicenter Study, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug eloralintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2`](#source-pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2`](#source-pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2))

### Sources

<a id="source-pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2"></a>
- **Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. · retained source version 1:2026-08-15:current:2fb96d76abf28060d09950cc955b7875b2b4d71deae7b1dc4830624139e7abf2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41559929/) (`pubmed-observation-pmid-41559929-2026-08-15-2fb96d76abf2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/eloralintide.json#pubmed-pmid-41559929-eloralintide-v1 SHA-256: c962511e5cc60853f11258ae95d6d46942e08dbab9a3cea8e07aa87cf3f97694.

